Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab in 1L Unresectable Intrahepatic Cholangiocarcinoma
NCT07353827Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of donafenib, pucotenlimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Sun Yat-sen University. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
donafenibpucotenlimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07353827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07353827.